Therapeutic Drug Monitoring and Population Pharmacokinetic Analysis of Teicoplanin among Chinese Patients with Gram-Positive Infections in a Tertiary Hospital

Table 5

Model parameters and verified results of final teicoplanin model.

	Final model		Bootstrap (N = 743)
	Estimate (RSE%)	95% CI	Estimate	95% CI
Parameters
CL (L/h)	0.239 (43.1)	0.04–0.44	0.332	0.05–0.80
Vc (L)	66.6 (14.4)	47.80–85.36	62.4	30.70–86.80
Q (L/h)	1.36 (16.4)	0.92–1.80	1.33	0.83–1.83
Vp (L)	488 (19.4)	302.19–673.81	392	101.00–1040.00
Weight on CL	3.97 (28.7)	1.74–6.20	3.39	0.73–7.32
Intertrial variability
ηCL	0.613 (33.2)	0.21–1.01	0.573	0.00–0.90
ηVc	0.667 (17.1)	0.44–0.89	0.666	0.31–0.90
ηQ	0.883 (21.1)	0.51–1.25	0.918	0.64–1.43
Residual error
ε (proportional)	0.253 (9.5)	0.21–0.30	0.241	0.17–0.31

CL: clearance rate; V_c: central volume of distribution; Q: intercompartmental clearance; V_p: peripheral volume of distribution.